Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?

Springer Science and Business Media LLC - 2017
R. El Tannouri1, E. Albuisson2,3, P. Jonveaux4, E. Luporsi5
1INSERM U954, University of Lorraine, Vandœuvre-lès-Nancy, France
2Faculty of Medicine, University of Lorraine, Vandoeuvre-lès-Nancy, France
3IECL CNRS, UMR 7502, BIOBASE, Pôle S²R, CHRU Nancy, InSciDens, Vandœuvre-lès-Nancy, France
4Human Genetics Laboratory, CHU Brabois, INSERM U954, University of Lorraine, Vandœuvre-lès-Nancy, France
5Institute of Oncology of Lorraine (ICL Alexis Vautrin), INSERM U954, University of Lorraine, Vandœuvre-lès-Nancy, France

Tóm tắt

The aim of the current analysis is to evaluate any differences of breast or ovarian cancer age at diagnosis between mothers and daughters carrying the c.3481_3491del11 mutation in the BRCA1 gene. A study cohort of 38 women carrying the c.3481_3491del11 mutation and affected by first breast or ovarian cancer who reported a first breast or ovarian cancer in their mother carrying the c.3481_3491del11 mutation, was identified in 37 different families including members with breast and/or ovarian cancer at the Oncology Institute of Lorraine. Twelve mothers underwent genetic testing. Twenty-five pairs of the 38 mothers-daughters pairs with c.3481_3491del11 mutation were affected by breast cancer and 13 pairs by ovarian cancer. Clinical and genetic data were collected from medical files and family pedigrees. Analyses were conducted for each cancer type. We investigated an early breast cancer detection effect due to early screening programs and also an increased breast tumor aggression. Since major improvements in breast cancer clinical management and imaging techniques appeared after 1980, we compared the age at breast cancer diagnosis and the age at death in mothers and daughters before and after 1980, first, in the group of women including mothers and daughters taken together and then in mothers and daughters separately. The mean age at breast cancer diagnosis was 45.28 ± 10.27 years in mothers and 39.80 ± 7.79 years in daughters (p = 0.026). The difference of age at ovarian cancer diagnosis in mother-daughter pairs was 8.62 ± 12.76 years (p = 0.032). When considering the group of women including mothers and daughters taken together, no significant difference of age at breast cancer diagnosis was found between women affected before 1980 and those affected after 1980 (p = 0.577). However, the age at death increased in these women after 1980 (p = 0.026). Comparison of age at breast cancer diagnosis in mothers and daughters separately, showed that daughters were affected at an earlier age after 1980 (p = 0.002). Daughters had a poor prognosis and died earlier than mothers after 1980. Our results may have reflected genetic anticipation in c.3481_3491del11 mutation breast and ovarian cancer families. In order to confirm our findings, a larger cohort would provide more precision to the difference of ages at breast or ovarian cancer diagnosis between mothers and daughters and more powerful statistical analyses. Increased aggression in daughters’ tumors compared to those of mothers could be also considered as a parameter of genetic anticipation. Complete information on tumor profile and proliferation would allow us to study genetic anticipation by comparing the tumor phenotypes between mothers and daughters in the future.

Từ khóa


Tài liệu tham khảo

Paterson AD, Kennedy JL, Petronis A (1996) Evidence for genetic anticipation in non-Mendelian diseases. Am J Hum Genet 59:264–268

Howritz M, Goode EL, Jarvik GP (1996) Anticipation in familial leukemia. Am J Hum Genet 59:990–998

Schols L, Bauer P, Schmidt T, Schulte T, Riess O (2004) Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 3:291–304

Nilbert M, Timshel S, Bernstein I, Larsen K (2009) Role for genetic anticipation in Lynch syndrome. J Clin Oncol 27:360–364

Westphalen AA, Russell AM, Buser M, Berthod CR, Hutter P, Plasilova M, Mueller H, Heinimann Karl (2005) Evidence for genetic anticipation in hereditary non-polyposis colorectal cancer. Hum Genet 116:461–465

Brown BW, Costello TJ, Hwang SJ, Strong LC (2005) Generation or birth cohort effect on cancer risk in Li–Fraumeni syndrome. Hum Genet 118:489–498

Tabori U, Nanda S, Druker H, Lees J, Malkin D (2007) Younger age of cancer initiation is associated with shorter telomere length in Li–Fraumeni syndrome. Cancer Res 67:1415–1418

Martinez-Delgado B, Yanowsky K, Inglada-Perez L, Domingo S, Urioste M, Osorio A, Benitez J (2011) Genetic anticipation is associated with telomere shortening in hereditary breast cancer. PLoS Genet 7(7):e1002182

Dagan E, Gershoni-Baruch R (2002) Anticipation in hereditary breast cancer. Clin Genet 62:147–150

Litton J, Ready K, Chen H, Gutierrez-Barrera A, Etzel C, Meric-Bernstam F Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK (2011) Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118(2):321–325

Peixoto A, Salgueiro N, Santos C, Varzim G, Rocha P, Soares MJ, Pereira D, Rodrigues H, Bento MJ, Fráguas A, Moura G, Regateiro F, Castedo S, Teixeira M (2006) BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. Familial Cancer 5:379–387

Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I (2004) Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 36(5):447–449

Mullan PB, Quinn JE, Harkin DP (2006) The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 25:5844–5586

Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108(2):171–182

Szabo CI, King MC (1995) Inherited breast and ovarian cancer. Hum Mol Genet 4:1811–1817

Rosen EM, Fan S, Pestell RG, Goldberg ID (2003) BRCA1 gene in breast cancer. J Cell Phys 196:19–41

Ford D, Easton DF, Stratton M, Narod S et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 3:676–689

Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130

Ramunas J (2010) Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J 1(3):397–412

Fricker JP, Muller D, Cutuli B, Rodier JF, Janser JC, Jung GM, Mors R, Petit T, Haegele P, Abecassis J (2000) Germ-line mutations at BRCA1 in northeastern France. Bull Cancer 87(10):739–744

Muller D, Bonaiti-Pellié C, Abecassis J, Stoppa-Lyonnet D, Fricker JP (2004) BRCA1 testing in breast and/ or ovarian cancer families from northeastern France identifies two common mutations with a founder effect. Fam Cancer 3:15–20

Myoung Noh J, Ho Choi D, Hyejin B, Kim MJ, Park H, Huh SJ, Park W, Nam SJ, Lee JE, Kil WH, Haffty BG (2014) Genetic anticipation of familial breast cancer with or without BRCA mutation in the Korean population. Cancer. Genet 270(4):160–163

Picard JD (1998) History of mammography. Bull Acad Natl Med 182(8):1613–1620

Feig SA (1987) Mammography equipment: principles, features, selection. Radiol Clin North Am 25:897–911

Kopans DB (1989) Breast imaging. JB Lippincott, Philadelphia

Tabar L, Fagerberg G, Duffy SW, Day NE (1989) The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Commun Health 43(2):107–114

Kalaf JM (2014) Mammography: a history of success and scientific enthusiasm. Radiol Bras 47(4):7–8

Junod B, Zahl PH, Kaplan R, Olsen J, Greenland S (2011) An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts. BMC Cancer 11:401

Binder-Foucard F, Belot A, Delafosse P, Remontet L, Woronoff AS, Bossard N (2013) Estimation de l’incidence et de la mortalité par cancer en France entre 1980 et 2012. Institut de veille sanitaire, Saint-Maurice

Association Pour le Dépistage des Maladies du Sein, ADEMAS-ALSACE. http://www.ademas-alsace.com/presentation-ademas-alsace.php. Accessed Sep 2016

ADECA 54 (2000) Bulletin d’information de l’Association pour la Promotion et l’Organisation du Dépistage du Cancer du Sein en Meurthe-et-Moselle. Mammo’TEXT, APODCS

Institut National du Cancer. Les cancers en France (2015) http://www.ecancer.fr/Expertises-et-publications/Catalogue-des-publications/Les-cancers-en-France-Edition-2015. Accessed Sep 2016

Frenel JS, Campone M (2010) Chimiothérapie des cancers du sein non métastatiques: état des lieux en 2010. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 39:F74-F84

Delozier T (2004) Le tamoxifène en situation adjuvante dans le cancer du sein : trente ans d’expérience. Société Française de Sénologie et de Pathologie Mammaire - SFSPM. 308–316. http://hdl.handle.net/2042/373

Kumar G, Badve S (2008) Milestones in the discovery of HER2 proto-oncogene and trastuzumab (Herceptin™). Connection 12:9–14

Whelan T, Julian J, Wright J, Jadad A, Levine M (2000) Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 18:1220–1229

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D et al (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129–6134

Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S (2008) Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13(6):620–630

Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153

Guindalini RS, Song A, Fackental JD, Olopade OI, Huo D (2016) Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer 122(12):1913–1920

Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP, Lesur A, Noguès C, Pierret J, Puy-Pernias S, Sobol H, Tardivon A, Tristant H, Villet R (2004) Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004). Bull Cancer 91(3):219–237

McCarthy M (1993) DDT and breast cancer. Lancet 341:1407

Cassidy RA, Natarajan S, Vaughan GM (2005) The link between the insecticide heptachlorepoxide, estradiol, and breast cancer. Breast Cancer Res Treat 90:55–64

Charlier C, Albert A, Herman P, Hamoir E, Gaspard U, Meurisse M, Plomteux G (2003) Breast cancer and serum organochlorine residues. Occup Environ Med 60:348–351

Cohn BA, Wolff MS, Cirillo PM, Sholtz RI (2007) Ddt and breast cancer in young women: new data on the significance of age at exposure. Environ Health Perspect 115:1406–1414

Ibarluzea JJ, Fernandez MF, Santa-Marina L, Olea-Serramo MF, Rivas AM et al (2004) Breast cancer risk and the combined effect of environmental estrogens. Cancer Causes Control 15:591–600

Institut National de Veille Sanitaire (2013) Exposition de la population française aux substances chimiques de l’environnement. INVS, Tome 2. http://www.invs.sante.fr/Espace-presse/Communiques-de-presse/2013/Exposition-de-la-population-francaise-aux-pesticides-et-PCB-NDL. Accessed Sep 2016

Expertise Collective INSERM-FNCLCC (1998) Risques héréditaires de cancers du sein et de l’ovaire. Quelle prise en charge ? INSERM, Paris

Soegaard M, Kruger Kjaer S, Cox M, Wozniak E, Hodgall E, Hogdall C, Blaakaer J, Jacobs IJ, Gayther SA, Ramus SJ (2008) BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res 14(12):3761–3767

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả